Observational studyScientific reports2025
A multi-center study on the predictors of different subtypes of hemorrhagic transformation of brain infarction after thrombolysis in atrial fibrillation patients presented with embolic stroke.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06653946 (the Predictors of Different ECASS-based Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients Treated With Alteplase), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
the Predictors of Different ECASS-based Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients Treated With Alteplase
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Intravenous thrombolysis versus antiplatelet standard care for patients with mild acute ischemic stroke: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Dynamic alterations of thrombotic molecular markers in acute ischemic stroke patients after intravenous thrombolysis: a prospective cohort study.BMC neurology · 2026Article
- Incidence, Predictors, and Outcomes of Symptomatic Intracranial Hemorrhage after Tenecteplase in Acute Ischemic Stroke.Annals of Indian Academy of Neurology · 2026Article
- Assessment of Socio-Demographic and Clinical Characteristics of Stroke Patients of a Tertiary Hospital in Bangladesh: A Cross-Sectional Study.Health science reports · 2026Article
- Interaction between age and atrial fibrillation on ischemic stroke severity: a cross-sectional analysis.Frontiers in stroke · 2026Article
- Predictors of Post-Alteplase Long-Term Unfavorable Outcome in Atrial Fibrillation Patients Presented with Embolic Stroke in the Middle East and North Africa Regions: A Multi-center, Longitudinal Study.Neurology and therapy · 2025Article
- Incidence and outcomes of hospitalized acute ischemic stroke patients with subsequent ST-segment-elevation myocardial infarction.Frontiers in cardiovascular medicine · 2025Article
- Prognostic Value of Glucose-to-Potassium Ratio in Acute Ischemic Stroke Patients Undergoing Thrombolysis and Its Interaction with Inflammation.Clinical interventions in aging · 2025Article
- The combination of atrial fibrillation and small vessel disease score worsen spontaneous intracerebral hemorrhage outcomes.Frontiers in neurology · 2025Article
- Risk factors and impact on outcomes of high-density shadow on immediate cerebral CT after successful interventional recanalization in acute ischemic stroke with large vessel occlusion.Frontiers in neurology · 2025Article
- Rehabilitation Combined with Coagulation Tests for the Prevention of DVT in Patients After Hypertensive Intracerebral Hemorrhage Surgery.Therapeutics and clinical risk management · 2025Article
- Imaging patterns of hemorrhagic transformation after tenecteplase versus alteplase in real-world practice.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Embolic stroke is connected to a higher risk of hemorrhagic transformation (HT), functional disability, and mortality. Although, AF and HT are not one entity; no such study evaluated the factors, including AF types and treatment, which could predict the different types of HT in AF patients presenting with embolic stroke and administered alteplase. We aimed to assess the predictors of HT in general and predictors of different ECASS-based subtypes of post-alteplase HT in AF patients who experienced first-ever embolic ischemic stroke. Our study included 716 AF patients who presented with acute embolic stroke and received the full recommended dose of alteplase. The study comprised six parallel groups. The first group consisted of 509 patients who did not experience haemorrhagic transformation. The second group comprised 207 patients who had any HT. The third group comprised 87 patients with haemorrhagic infarction (HI)1. The fourth group comprised 62 patients with HI2. The fifth group comprised 33 patients with parenchymal hematoma (PH) 1, and the sixth group comprised 25 patients with PH 2. We evaluated the ability of different baseline characters and risk factors to predict the occurrence of HT in general and the predictors of occurrence of different ECASS-based HT subtypes. HT was detected in 207 patients (28.9%), older age, higher NIHSS, sustained AF, warfarin use, and higher HAS-BLED score were independent predictors of all ECASS-based subtypes of hemorrhagic transformation; moreover, anterior-circulation stroke was an independent predictor of PH 1 and PH 2. In atrial fibrillation patients presented with first-ever embolic stroke and received alteplase in Egypt and the United Arab Emirates, older age, higher NIHSS, sustained AF, warfarin use, and higher HAS-BLED score were independent predictors of all ECASS-based subtypes of haemorrhagic infarction; in addition, anterior-circulation stroke was an independent predictor of PH 1 and PH 2.Trial registration (clinicaltrials.gov NCT06653946), retrospectively registered on 23/10/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.